Scarica l'app Stockscreener
9.21
5.86%
0.51
Dopo l'orario di chiusura:
9.27
0.06
+0.65%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$8.70
Aprire:
$8.72
Volume 24 ore:
9.61M
Relative Volume:
1.72
Capitalizzazione di mercato:
$2.40B
Reddito:
$6.22B
Utile/perdita netta:
$187.00M
Rapporto P/E:
12.85
EPS:
0.7166
Flusso di cassa netto:
$508.00M
1 W Prestazione:
+57.17%
1M Prestazione:
+45.04%
6M Prestazione:
-3.56%
1 anno Prestazione:
-16.65%
Intervallo 1D:
$8.335
$9.35
Intervallo di 1 settimana:
$5.82
$9.35
Portata 52W:
$5.69
$13.24
Organon Co Stock (OGN) Company Profile
Nome
Organon Co
Settore
Industria
Telefono
551-430-6000
Indirizzo
30 HUDSON STREET, JERSEY CITY
Compare OGN vs LLY, JNJ, ABBV, AZN, MRK
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
9.21 | 2.26B | 6.22B | 187.00M | 508.00M | 0.7166 |
LLY
Lilly Eli Co
|
905.03 | 824.12B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
238.67 | 578.31B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
208.42 | 371.90B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
201.21 | 316.96B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
117.90 | 296.29B | 64.93B | 18.26B | 12.36B | 7.2751 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Underweight |
| 2025-10-27 | Downgrade | Piper Sandler | Overweight → Underweight |
| 2025-05-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-09-06 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-11-03 | Downgrade | Goldman | Buy → Neutral |
| 2023-09-21 | Iniziato | Barclays | Overweight |
| 2023-03-16 | Iniziato | Raymond James | Outperform |
| 2022-10-14 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-09-06 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-10-07 | Iniziato | Piper Sandler | Neutral |
| 2021-09-01 | Iniziato | BofA Securities | Buy |
| 2021-07-22 | Iniziato | Citigroup | Buy |
| 2021-06-15 | Iniziato | JP Morgan | Neutral |
| 2021-06-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-06-10 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Organon Co Borsa (OGN) Ultime notizie
AAD recommends Organon’s VTAMA cream for pediatric atopic dermatitis - Investing.com
Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis - Business Wire
Organon & Co. Shares Drop 6.4% as Analysts Forecast Weak Growth - National Today
Organon (OGN) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo! Finance Canada
Organon rises as Sun Pharma said to near $12B buyout deal - MSN
3 Reasons to Avoid OGN and 1 Stock to Buy Instead - Yahoo Finance
Unusually active option classes on open April 13th - TipRanks
Organon Takeover At $15? Probably Not, Here's Why (NYSE:OGN) - Seeking Alpha
Organon Stock Skyrockets 28% Following Reports of $12 Billion Buyout Offer From Sun Pharma - TIKR.com
Sun Pharma’s Reported US$12b Bid Recasts Organon’s Risk Reward Profile - Sahm
American pharmaceutical MSD receiving billions in tax benefits in the Netherlands - NL Times
Sun Pharma Officially Denies $12 Billion Organon Acquisition Speculation - scanx.trade
EBIT per share of Organon & Co. – SWB:7XP - TradingView — Track All Markets
Is Organon (OGN) Now An Opportunity After Its Recent Share Price Surge? - Yahoo Finance
Buy or Sell Organon Stock in 2026? Takeover Buzz Lifts Shares 28% as Analysts Stay Cautious - International Business Times Australia
Institutional Money Floods Organon as Analysts Warn and Charts Conflicted - Bitget
Organon (OGN) Climbs 39% on $12-Billion Merger Buzz - Insider Monkey
Key deals this week: Organon, UMG, Whitestone REIT, Gilead and more - Seeking Alpha
Avoiding Lag: Real-Time Signals in (OGN) Movement - Stock Traders Daily
Organon Shares Soar as Sun Pharmaceutical Eyes $12B Deal - timothysykes.com
Morning Movers: Organon jumps after report of Sun Pharmaceutical bid - Yahoo Finance
Sun Pharma Nears Final Offer For Organon In Largest Overseas Bet - Sahm
What does Sun Pharma gain from its $12-billion Organon bid? - Business Today
OGN Analyst Rating Maintained at Outperform by BNP Paribas - Meyka
Sun Pharma Submits $12B Bid for Organon, Shares Surge - Intellectia AI
This Women’s Health Company Is Drawing Takeover Interest. The Stock Is Soaring. - Barron's
BNP Paribas Maintains Organon & Co(OGN.US) With Buy Rating, Cuts Target Price to $15 - Moomoo
Morgan Stanley Maintains Organon & Co(OGN.US) With Hold Rating, Maintains Target Price $9 - Moomoo
Organon (OGN) Stock Rockets 41% as Sun Pharma Submits $12B Buyout Proposal - MEXC
Organon (OGN) Stock Surges 41% on $12 Billion Sun Pharma Takeover Bid - MEXC
Organon Shares Surge on $12 Billion Takeover Bid from Sun Pharma - AD HOC NEWS
Sun Pharma readies $12B offer for Organon: report - FirstWord Pharma
Sun Pharma Plans USD 12 Billion Organon Acquisition, Prepares Binding Bid: Report - Medical Dialogues
Organon Rumors Persist Despite Sun’s Fresh Denial - Citeline News & Insights
Potential Acquisition Rumors Keep Organon (OGN) on the Rise - GuruFocus
Organon, CoreWeave, WhiteFiber And Other Big Stocks Moving Higher On Friday - Benzinga
Sun Pharma's $12B Organon Bid Rumors Spark Stock Drop, Debt Fears - Whalesbook
Organon & Co. (OGN) is attracting investor attention: Here is what you should know - MSN
M&A News: Organon Stock (OGN) Surges 26% on Reported Sun Pharma Bid - TipRanks
US Stocks Mixed; Dow Falls Over 100 Points - Benzinga
Organon & Co. (OGN) is Drawing Interest from Investors: Key Information You Need to Know - Bitget
Sun Pharmaceutical to proceed with $12B bid for Organon, Economic Times says - TipRanks
Evercore Maintains Organon & Co(OGN.US) With Hold Rating - 富途牛牛
Sun says Organon takeover report ‘speculative in nature’ - TipRanks
Organon deal interest report bodes well for sector valuation, says Evercore ISI - TipRanks
Organon Stock Explodes 17% on Takeover Speculation as Women's Health Drugmaker Draws Buyer Interest - International Business Times Australia
This Women’s Healthcare Stock Is Up 15% on Reports of a Takeover In the Works - Yahoo Finance
Organon’s Phase 3 Data Boosts Vtama Cream’s Market Potential - timothysykes.com
These Stocks Are Today's Movers: Lumentum, Coherent, Sandisk, Palo Alto, Organon, Palantir, and More -- Barrons.com - Moomoo
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
OGN stock surges 20% pre-market, on track to break 200-DMA – why this buyout report has caught investor attention - MSN
Organon Co Azioni (OGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.30%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):